The 3-Month Clinical Response to Intravesical Therapy as a Predictive Factor for Progression in Patients With High Risk Superficial Bladder Cancer

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016

“…The response to intravesical treatment with BCG or chemotherapy is an important prognostic factor for subsequent progression and death caused by BCa [57,61]. Approximately 10-20% of complete responders eventually progress to muscle-invasive disease, compared with 66% of nonresponders [65] (LE: 2a).…”

“…Some authors have even defended temporary surveillance in selected cases [121] (LE: 3). The first cystoscopy after TURB at 3 mo is an important prognostic indicator for recurrence and progression [61,65,122,123] (LE: 1a); therefore, the first cystoscopy should always be performed 3 mo after TURB in all patients with TaT1 tumours and CIS.…”

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

“…Prior studies have suggested that several clinicopathologic parameters, such as tumor size [10,11], multiplicity [10], morphology [12], concomitant carcinoma-in-situ (CIS) [10,11], and response to intravesical therapy [13] are risk factors for tumor progression and patient mortality in T1G3 BC. However, the results of these studies are inconsistent; meanwhile, some studies found no prognostic value of such clinicopathologic parameters in T1G3 BC [14].…”

Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance

“…There is also heterogeneous recognition of the category pTa-G3 in the urologic literature. Some authors define it as a large population within high-risk superficial bladder cancer [10,21] while others omit this category altogether [22].…”